



The Medicines Patent Pool Foundation

Board Resolution

3 October 2022 (via correspondence)

The Governance Board of the Medicines Patent Pool (MPP) thanks the Expert Advisory Group (EAG) for their report assessing the final results of negotiations between MPP and Shionogi & Co., Ltd (Shionogi) on the proposed licence agreement for ensitrelvir fumaric acid (Agreement).

The Board has reviewed the EAG report assessing the proposed Agreement. The Board agrees with the EAG's assessment that the proposed collaboration is consistent with the MPP's mandate as defined in its Statutes, and that the Agreement represents a significant improvement over the status quo. Therefore, the Board requests the Executive Director to finalise and sign the necessary documents with Shionogi to formalise this collaboration.